BillionToOne is a precision diagnostics company specializing in ultra-sensitive prenatal and oncology testing, and this weekly summary reviews a series of strategic, commercial, and visibility-enhancing developments for the firm. During the week, BillionToOne announced a major health IT integration with Epic, new financial guidance for 2026, and increased executive and technology visibility through a prominent media profile.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The most significant operational news is BillionToOne’s collaboration with Epic to integrate its core assays—UNITY Complete, Northstar Select, and Northstar Response—into Epic’s Aura diagnostics suite and broader electronic health record ecosystem. Clinicians using Epic will be able to order these tests directly within their existing workflows, with structured results automatically returned to the patient record and made available via MyChart. This integration is designed to reduce ordering friction, standardize reporting, and enable clinical decision support across health systems, maternal-fetal medicine practices, and oncology clinics. Strategically, embedding BillionToOne’s tests in the most widely used U.S. EHR platform should expand access, support higher test utilization, and deepen the company’s role in routine prenatal and cancer care, although actual adoption will depend on implementation quality and provider uptake.
On the financial side, BillionToOne issued 2026 revenue guidance of $415 million to $430 million, implying approximately 40–45% year-over-year growth, while reaffirming expectations for positive GAAP operating income. This outlook suggests the company is benefiting from operating leverage as its prenatal and oncology portfolios scale, potentially reducing reliance on external capital and strengthening its position in the competitive molecular diagnostics market. Achieving these targets will require sustained demand, favorable reimbursement, and effective execution amid industry competition and regulatory dynamics.
The company also highlighted a leadership profile of CEO Oguzhan Atay, PhD, in Onyx’s CEO feature series for The Onyx Life Sciences Report, slated for publication in Fortune in 2026. The feature emphasizes BillionToOne’s physics-informed technology platform and growth trajectory, potentially boosting brand awareness among clinicians, partners, investors, and prospective employees.
Overall, the week marked a combination of commercial progress, financial visibility, and brand-building for BillionToOne, reinforcing its ambitions to scale its prenatal and oncology diagnostics franchise while maintaining profitable growth.